Citigroup
CTNM

Citigroup’s Contineum Therapeutics CTNM Stock Holding History

Citigroup’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$216K Buy
13,193
+4,333
+49% +$56.8K ﹤0.01% 4306
2026
Q1 		$116K Sell
8,860
-3,464
-28% -$46.5K ﹤0.01% 4229
2025
Q4 		$141K Buy
+12,324
New +$141K ﹤0.01% 4159
2025
Q3 		– Sell
-1,774
Closed -$7.04K – 6360
2025
Q2 		$7.04K Sell
1,774
-5,613
-76% -$24.4K ﹤0.01% 5239
2025
Q1 		$51.6K Sell
7,387
-890
-11% -$8.1K ﹤0.01% 4860
2024
Q4 		$121K Buy
8,277
+3,395
+70% +$53.8K ﹤0.01% 4734
2024
Q3 		$93.4K Buy
4,882
+3,353
+219% +$64.3K ﹤0.01% 4791
2024
Q2 		$26.9K Buy
+1,529
New +$24.6K ﹤0.01% 4906

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citigroup's CTNM Position: Q2 2026 in Review

Citigroup increased its Contineum Therapeutics (CTNM) stake by 49% in Q2 2026, buying an estimated $56.8K and bringing the position to 13,193 shares worth $216K. The position accounts for ﹤0.01% of the portfolio, ranked #4306.

Citigroup first reported a position in CTNM in Q2 2024 and has held it in 8 quarters since. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Citigroup held 13,193 shares of Contineum Therapeutics worth $216K as of Q2 2026.
  • Citigroup bought 4,333 Contineum Therapeutics shares in Q2 2026, an estimated $56.8K.
  • Contineum Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4306 holding.
  • Citigroup first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.